In this Bioanalysis Zone interview, Stephanie Traub (Cancer Research UK; London, UK) discusses her work as a biomarker specialist and the challenges she faces when developing biomarker strategies. Stephanie also explains the role of non-LBA assays for biomarker validation, before sharing what new technologies this field has seen in recent years.
If you enjoyed this interview, you might also like…
Recommendations for classification of commercial LBA kits for biomarkers in drug development from the GCC for bioanalysis
Flow cytometry: a flexible tool for biomarker research
Biomarker validation and flow cytometry: an interview with Rafiq Islam